Organic Active Ingredients TRIZ Cases

Using asenapine acid addition salt with a desalting agent in an acrylic adhesive patch reduces degradation during manufacturing while preserving efficacy.

Targeting TA-MUC1 with an antibody-drug conjugate delivers exatecan into resistant cancer cells, extending options beyond existing ADCs.

Bicyclic amines selectively inhibit CDK2 to treat cancers with deregulated CDK2 activity and help address resistance in CCNE1-driven tumors.

Chemically modified AAV capsids add cell-specific ligands to improve transduction while reducing liver off-targeting, toxicity, and dose needs.

SBEβCD inclusion complexation with bicarbonate raises meloxicam solubility and absorption, supporting rapid and sustained pain relief.

CMP conjugates target therapeutic compounds to diseased tissue, reducing systemic side effects, dosage needs, and supporting faster healing.

Phytoecdysones restore the ACE2/Ang-1-7/MasR pathway to treat viral respiratory impairment while avoiding hypotensive effects.

Solid PVA-based microspheres carry chemotherapy drugs and iodine-131 for lasting embolization, slow release, and real-time tumor imaging.

A crystalline salt form of a plasma kallikrein inhibitor improves oral formulation while helping prevent thrombus reocclusion and bleeding.

A multi-arm CD44-targeted conjugate improves tumor-specific drug concentration while reducing normal-cell toxicity in high-CD44 cancers.

Olive leaf extract with oleuropein and oleuroside activates HIF-1 to support stem cell state control and improve hematopoiesis and vascular function.

Guanidinium-functionalized polylysine uses electrostatic attraction to target pathogens and cancer cells while broadening activity and reducing resistance.

Immunosuppressants such as tacrolimus or dexamethasone reduce xenogeneic immune rejection and improve mesenchymal stem cell survival.

Selective triazolone antagonists target A2aR and A2bR while preserving solubility and limiting CB-1 off-target binding to enhance antitumor immunity.

Carboxylic acid azetidinyl compounds target S1P5 to support myelin formation and slow neurodegenerative disease progression.

Crystalline salt forms of a CFTR modulator improve stability and purity while preserving dissolution needed to enhance anion transport in cystic fibrosis.

Small-molecule PCSK9 inhibitors replace injectable antibodies with oral compounds that lower LDL cholesterol and support sepsis treatment.

A pH-dependent gamma-hydroxybutyrate formulation splits release across acidic and neutral media to match twice-nightly exposure in one dose.

Novel selenoxoimidazolidine compounds inhibit NOX, limit α-synuclein aggregation, and protect dopaminergic neurons from ROS-driven death.

A nonionic dexketoprofen-lidocaine associated form enables sustained transdermal release without permeation enhancers, reducing irritation.

By targeting conserved Cra4S1 and outer membrane antigens, this vaccine improves stable protection against P. gingivalis strains.

Buffered pH 6-8 clonidine oral liquid uses phosphate salts and propylene glycol to improve stability, taste, and ready-to-use dosing.

Mucin-derived glycopeptides help infant formula promote Bifidobacterium and Lactobacillus while limiting pathogenic gut bacteria.

N4-hydroxycytidine derivatives and aerosol formulations help prevent or treat alphavirus and flavivirus infections by lowering viral load.

A pine bark, berry extract, and L-theanine blend improves mental clarity without caffeine jitteriness or unwanted ingredient interactions.

A bioerodible ocular insert delivers vorolanib locally with sustained release for up to 270 days while minimizing systemic toxicity and repeat dosing.

Formula (I) ASK-1 inhibitor compounds balance broad therapeutic use across liver, inflammatory, and neurodegenerative diseases with manageable development complexity.

PEGylated stealth liposomes improve MRSA antibiotic delivery by boosting infection-site accumulation, biofilm penetration, and kidney safety.

Substituted imidazolecarboxamide compounds inhibit BTK to extend treatment beyond cancer into autoimmune, inflammatory, and allergy indications.

Targeted lipid nanoparticles deliver CAR or TCR nucleic acids into T cells, cutting viral vector cost, production time, and antigenicity.

Allosteric M4 modulators improve receptor selectivity beyond the conserved orthosteric site, aiming to reduce peripheral cholinergic side effects.

High-pressure homogenized phospholipid micelles improve pregabalin skin absorption, extending topical neuropathic pain relief beyond five hours.

Combining PARP inhibitors with deoxyuridine analogs drives selective DNA damage in p53-deficient cancers while sparing wild-type cells.

Multiple crystalline, amorphous, and solvated FGFR inhibitor forms improve handling, stability, dissolution, and bioavailability for cancer therapy.

Novel neuroactive steroid compounds modulate GABAA receptors to treat CNS disorders while addressing side effects seen with older therapies.

Local sex steroid release at a repaired enthesis promotes healing genes, lowers re-tear risk, and avoids systemic hormone exposure.

Novel pharmacological chaperones enhance glucocerebrosidase activity to limit protein aggregation and treat Gaucher's and CNS degenerative disorders.

Crystalline Form A of leflutrozole enables high-purity dosing that raises testosterone and lowers estradiol without daily application.

Oral trigonelline raises intracellular NAD+ through metabolic conversion, supporting mitochondrial function in aging, metabolic, and neurodegenerative states.

An oral benzothiazole aniline composition shrinks liver tumors while reducing the toxicity seen with cisplatin treatment.

A quinoline IDO inhibitor is paired with HDAC modulation to improve immune regulation and treatment potential in tryptophan metabolism disorders.

Ulipristal-based dengue therapy blocks viral entry into host cells and pairs with GOViRA screening for faster, reproducible antiviral analysis.

Separate chambers keep polymer, cationic compound, and drug stable until mixing, enabling easy nanoparticle formation for drug delivery.

Using the S(−)-cibenzoline enantiomer, this case shows a composition that lowers LVOT gradient and improves symptoms in hypertrophic cardiomyopathy.

A pentaaza macrocyclic ring complex is combined with checkpoint inhibitors to sensitize tumors and strengthen immune response against cancer cells.

Baseline TIMP1, pro-MMP10, and PECAM1 levels guide ivaltinostat maintenance therapy in PDAC to improve survival while limiting toxicity.

Digital monitoring of mood, response, and interaction data helps personalize 5-MeO-DMT benzoate dosing for more reliable treatment outcomes.

Specific KIT inhibitor compounds target mast cells more precisely, reducing healthy-cell side effects while improving treatment of KIT-mediated diseases.

Isolated mitochondria-rich organelle complexes reprogram T cells to improve expansion, persistence, cytotoxicity, and resistance to exhaustion.

A heterologous probiotic blend eases menopause symptoms while supporting bone density through gut microbiome shifts and vitamin K2 biosynthesis.

A modular sensor-transducer circuit reprograms B and T cells to detect pathological ligands and trigger localized therapeutic protein expression.

A nicotine-cellulose encapsulated oral composition speeds saliva-driven nicotine release and absorption while reducing total nicotine content.

Alternating RNA-DNA fusomers form DNA-core, RNA-loop fibers that deliver therapeutics while reducing immunostimulation.

A PHD-inhibiting compound stabilizes HIFs to reduce inflammation, oxidative stress, and proteinuria in glomerular disease.

Targeted liver delivery of Factor XII RNAi suppresses FXII upstream to prevent thrombosis and angioedema with lower bleeding risk.

Sugar-lipid co-milled composite particles cut inhalation powder cohesion while preserving crystalline API stability and deep-airway delivery.

Bifunctional compounds recruit ERα to cereblon E3 ligase for ubiquitination and degradation, helping address resistance in ERα-driven disease.

Biodegradable PLGA disc particles improve lung accumulation and sustained drug release while limiting side effects in pulmonary disease treatment.

Non-systemic TGR5 agonists improve intestinal health and glucose regulation while reducing hypoglycemic, weight gain, and GI side effects.

Combining durvalumab with platinum chemotherapy before and after cystectomy helps cut recurrence and improve survival in muscle-invasive bladder cancer.

Selective GRK5 inhibitor compounds improve treatment specificity by combining potent kinase inhibition with disease-specific targeting.

Small-molecule HER3 ligands with degradation-increasing moieties improve brain penetration and target engagement for cancer treatment.

Oxaliplatin cocrystals help control rheumatoid arthritis progression and recurrence while lowering toxicity and resistance limits.

Combining methotrexate with AP1189 improves anti-arthritic response while helping reduce MTX toxicity and side effects.

A compound induces IL-10 production in immune cells to restore dominant immune regulation and reduce relapse, resistance, and side effects.

Candida lipase selectively converts cortexolone 17,21-diesters to stable 17α-monoesters, avoiding basic hydrolysis by-products and chromatography.

Polymer-linked camptothecin prodrugs use labile ester bonds to sustain intratumoral drug levels in neuroblastoma while limiting systemic toxicity.

Bridging target proteins with E3 ligases enables selective anti-cancer activity against resistant tumors with fewer adverse side effects.

Colon-release bile acid binding pairs with IBAT inhibition to lower plasma cholesterol while reducing diarrhea from excess colonic bile acids.

pH-responsive acetal lipids keep LNPs stable in blood, then hydrolyze in endosomes to boost mRNA delivery while reducing toxicity.

Ionizing tranexamic acid with mandelic acid improves skin permeability and bioavailability while maintaining efficacy with lower irritation.

Novel fluorinated antimalarial compounds modify the lumefantrine scaffold to treat resistant Plasmodium falciparum and block parasite replication.

Cell-permeable tricyclic PARG inhibitors restore DNA damage sensitivity in PARP inhibitor-resistant cancer cells.

Selective triazolopyrimidine and triazolopyrazine antagonists block A2A/A2B signaling to restore T-cell activity and inhibit tumor growth.

A dual TRK/RET inhibitor scaffold improves therapeutic efficacy while lowering side-effect burden across cancer, autoimmune disease, and wound-healing use.

Novel DMT fumarate, succinate, malate, sulfate, and oxalate salts improve solubility, melting point, and storage stability for formulation.

Bupropion inhibits TBZ metabolism to raise plasma levels and extend half-life, enabling less frequent dosing for neurological disorders and pain.

A biodegradable polyester matrix enables intranasal fluticasone release for 6-12 months, reducing frequent spray dosing for chronic rhinitis.

Selective heteroaryl NaV1.8 inhibitors improve pain relief coverage while widening the therapeutic window and limiting side effects.

Raising TDP with TPK agonists targets impaired glucose metabolism in Alzheimer's disease and may improve treatment effectiveness.

Novel azaindole STAT6 modulators balance stability, permeability, and solubility to enable oral and topical treatment with fewer systemic side effects.

Nitrogen heterocyclic compounds maintain PRMT5 inhibition under elevated MTA in MTAP-deficient cells, helping reduce cell proliferation.

Sulfamide-based P-CABs inhibit H+/K+-ATPase for faster onset, longer pH control, and improved stability beyond conventional PPIs.

Engineered recombinase libraries enable precise DNA payload integration at user-defined genomic loci without inefficient multi-step editing.

Targeting SVA-derived RNA transcripts with inhibitory nucleic acids may extend XDP treatment beyond temporary symptom relief.

Uniform 30-90 μm dutasteride microparticles enable 3-6 month release, stable plasma levels, and lower injection discomfort.

Small CD4 mimetics open HIV-1 Env to expose hidden epitopes, boosting antibody binding and ADCC against infected cells.

NOTA- and DOTA-linked risedronic acid improves bone lesion uptake, stability, and imaging quality for metastatic bone tumor diagnosis and therapy.

Using a chimpanzee adenovirus vector, this case improves neoantigen presentation while avoiding pre-existing immunity that can weaken cancer vaccines.

Solvent washing and anti-solvent crystallization replace column chromatography to deliver high-purity Vilanterol Trifenatate at scale.

A uridine-phenylacetate prodrug addresses ammonia buildup and uridine dosing limits by boosting plasma uridine while scavenging ammonia.

A PEG-based non-aqueous semi-solid keeps low-dose Compound I uniform and stable while enabling immediate release for CB1/CB2 therapy.

Controlled pH and dosing sequence keep levofloxacin and ketorolac compatible in one ophthalmic solution without precipitation.

Proline co-crystallization selectively isolates the α-anomer of novologue 4, raising purity and enabling scalable production with better bioavailability.

Cyclodextrin-based MOFs load hydrophobic drug anions while improving solubility, stability, and oral bioavailability.

A tocopherol-based ocular depot forms a thin film that sustains drug release for days while avoiding frequent dosing and vision impairment.

Salt forms and excipient selection improve dissolution, oral absorption, and tolerability for nephropathy treatment with lower side effects.

Formula I compounds selectively inhibit PRMT5 to improve treatment of multiple sclerosis, transplant rejection, and inflammatory disease.

Bridged tricyclic carbamoylpyridones extend half-life and stability to reduce HIV dosing frequency, interactions, and adherence burden.

Substituted pyrazolo-pyrimidines inhibit PIKfyve to raise PI3P and stimulate autophagy for treating FIG4-linked neurological disorders.

Formula (A), (I), and (II) EGFR inhibitor compounds target exon20 insertion mutants and address resistance to approved anti-EGFR therapies.

See how non-internalizing LGALS3BP ADCs release cytotoxic drugs extracellularly, bypassing target internalization in cancer cells.

InflammaProbe-1 targets NLRP3 inflammasomes and macrophages for ocular imaging while supporting in vivo use without retinal toxicity.

Biomarker levels in blood or bronchoalveolar lavage fluid can flag CLAD risk before pulmonary function decline, enabling earlier treatment.

Ex vivo expansion with IL-15, nicotinamide, CD3 stimulation, and cryopreservation addresses low NK-cell numbers and short persistence after infusion.

Defined serum-free media support temporary cell and tissue storage, wound irrigation, and infusion while preserving viability.

Proteasomal removal of PTPN2/PTP1B by degrader compounds addresses incomplete checkpoint therapy responses and resistance.

Staged plasma exchange, oral chelators, and IV supplementation address chronic toxin exposure while sustaining detoxification.

Phenyl-linked pyrimidine modifications improve aptamer nuclease stability, serum half-life, and target binding.

Hydroxyurea can cause genotoxicity and neutropenia; these compounds reduce WIZ protein levels to induce HbF for blood-disorder treatment.

The c.932G>A NR2E3 mutation causes aberrant splicing; splice-shifting ASOs restore exon 6 inclusion and full-length protein.

New anhydrous, hemisuccinate, and dihydrate forms address stability limits in ribociclib succinate compositions.

Systematic R-group variation in pyrazine derivatives improves SHP2 inhibition for treating non-receptor phosphatase diseases.

Circular RNA uses IRES elements and nanoparticle delivery to express therapeutic proteins without genomic integration or viral vectors.

Soluble DNA or mRNA antigens are enclosed in oxidation-stable polymersomes to reduce antigen needs and strengthen antibody and CD8(+) T-cell responses.

Existing SHP2 inhibitors can suppress the target yet lack brain penetration; pyrazolopyrazine compounds address both properties.

Amorphous KRAS G12C inhibitor forms can limit dissolution and bioavailability; defined crystalline forms target solubility and storage stability.

A quinoline compound is combined with other therapies to improve metastatic Ewing's sarcoma treatment and limit chemotherapy side effects.

Combining tubulin polymerization inhibition with PARP blockade targets microtubules and DNA repair to address multidrug-resistant ovarian cancer.

Probenecid blocks ion channels and neurotransmitter release to inhibit clinical and electrographic seizures in treatment-resistant epilepsy.

Supercritical propane, carbon dioxide, and hexane extraction preserves oleocanthal before debittering for malt supplement use.

A 0.70–1.50 mg/cm² diclofenac sodium adhesive layer supports lumbago relief from non-lumbar application sites.

A biodegradable PLGA implant co-delivers ketamine and norketamine to sustain fibromyalgia pain relief while limiting medication side effects.

Alternative-site ligands modulate PREP beyond active-site inhibition, inducing autophagy and activating PP2A to address protein aggregation.

Room-temperature degradation limits aqueous aceclidine storage; pH 4.5–5.5 retains at least 90% purity for up to 6 months.

This case addresses EGFR-mediated brain metastases with derivatives that reach therapeutic brain concentrations and inhibit resistant T790M mutations.

RNAi agents, antisense oligonucleotides, and inhibitory antibodies target COX7A1 to address limited mammalian regeneration and support scarless wound healing.

CIDEB-targeting iRNA uses RISC-mediated gene silencing to interrupt the inflammation and tissue-damage cycle in NASH.

Separating fine nicotine from larger flavor particles directs each component to the lungs or mouth at conventional inhalation rates.

By modifying fulvestrant's structure, these compounds target ERα degradation and anti-proliferation in MCF-7 cells for mutation-linked breast cancer resistance.

Cationic carriers can introduce plasmid DNA but often underperform with mRNA; hydrophobic side chains add membrane interaction for endosomal escape.

A prefilled, single-use autoinjector delivers 0.1–0.5 mg/mL ergoline derivatives at home to address treatment delays and side effects.

Modified resistant maltodextrin reshapes gut microbiota to improve sleep quality and cognition without direct brain intervention.

New crystalline, hydrate, and solvate forms of Compound 1 address purity and characterization gaps while supporting solubility, stability, and bioavailability.

Replacing ethanol and polysorbate 80 with cyclodextrin, co-solvents, and stabilizers addresses adverse effects while supporting high solubility and stability beyond 24 months.

PROTAC molecules recruit E3 ubiquitin ligase activity to degrade IRAK4, addressing resistance linked to its kinase and scaffold functions.

A subcutaneous olanzapine formulation combines diblock and triblock copolymers to support monthly dosing while reducing PDSS risk.

Treatment-resistant seizures and antiepileptic side effects are addressed through an oxadiazole derivative that potentiates GABA(A) receptors.

Forming a crystalline fumarate salt stabilizes an MEK inhibitor while supporting pharmaceutical processing and storage.

A staged regimen adjusts initial, interim, and maintenance orismilast doses by body mass to balance efficacy and gastrointestinal tolerability.

Rapid upper-tract absorption and a short half-life are addressed by bentonite, which adsorbs vactosertib at low pH and releases it in the bowel.

Reversible clusters of drug-loaded nano-resin particles decluster under eye shear to improve corneal penetration and extend ophthalmic action.

Selective A2A/A2B blockade targets tumor-associated immunosuppression while supporting combination immunotherapy with checkpoint inhibitors.

Peptide intermediaries target acidic or hypoxic cancer tissue to deliver topoisomerase I inhibitors while limiting systemic side effects.

A Papiliotrema terrestris beta-galactosidase converts lactulose into fGOS, avoiding lactose while retaining high GOS content and functionality.

React 4-amino-3-hydroxybenzoic acid with a 3,5-dichlorophenyl orthoester to improve output, stability, and solubility.

Rapid bromfenac release can shorten pain control; a collagen or gelatin matrix with a divalent metal salt sustains delivery for 7 days.

Calcium silicate supports stable, well-disintegrating eltrombopag tablets while enabling dose-proportional strengths.

Laser imaging and sensors guide selective debridement, removing necrotic tissue while helping preserve newly formed healthy tissue.

This case shows how isolating GDC-0077 Forms A, B, and D through controlled crystallization improves manufacturing consistency and stability.

A bioimplantable structure forms a nano-turf surface via dry-etched polymer layers to enable controlled drug release while inhibiting cell proliferation.

Lipoyl compounds treat ischemia-reperfusion injury by inhibiting cell death and reducing myocardial infarct area.

Analyzing miRNA levels in biological samples identifies cerebral vasospasm risk, enabling early intervention before neurological deficits occur.

RNA interference molecules silence voltage-dependent anion channel 1 expression to attenuate cellular proliferation.

A portable soft mist inhaler delivers pre-filled iloprost doses via aerosol for rapid pulmonary absorption.

Novel compounds of Formulas I-VIII deliver enhanced receptor selectivity to overcome insufficient specificity in existing drug therapies.

Single-use vials eliminate preservative side effects while maintaining microbial sterility through aseptic filtration and in-situ sterilization.

Pulmonary aerosol delivery of rapamycin achieves therapeutic lung concentrations while minimizing systemic toxicity and cancer risk.

Viscous ophthalmic gel resists tear washout to maintain therapeutic aldose reductase inhibitor levels, reducing dosing frequency and liver metabolism risks.

Formula I compounds inhibit SARS-CoV-2 main protease, addressing limited efficacy of existing treatments.

N-benzenesulfonyl gamma-aminobutyric acid derivatives inhibit epidermal SCCA expression, restoring skin barrier function and reducing wrinkle volume.

Serial passage adaptation modifies the viral genome to resolve trade-offs between safety and efficacy against mutated strains.

Multimodal chromatography purifies extracellular vesicles loaded with cyclic dinucleotides for targeted delivery.

C10-C11 ester compounds block proinflammatory cytokine secretion to prevent organ damage while preserving infection elimination.

A KRAS G12C inhibitor compound impairs protein function in cancer cells.

A coated feed additive composition strengthens intestinal epithelial cell membranes to improve livestock body weight gain and feed conversion ratio.

A diarylmethane carboxylic acid compound inhibits urate transporter 1 activity.

Replacing cyclodextrin with phospholipid-based components and cholesterol improves solubility while enabling stable subcutaneous administration.

Segmented pyridine compounds improve clinical efficacy and safety by reducing pro-inflammatory mediators.

Amorphous API dispersion in a polymer matrix overcomes poor solubility and high melting points, enabling immediate drug absorption.

Stem-loop aptamers inhibit complement factor D, addressing the lack of approved treatments for dry age-related macular degeneration.

Amphiphilic peptides protect siRNA from enzymatic degradation and rapid clearance, enhancing intracellular gene silencing.

Selective EP2 and EP4 receptor antagonism reactivates the tumor immune system while preserving cardiovascular protective prostanoids.

Targeting Src kinase with saracatinib reduces fibrosis markers while avoiding adverse side effects common in pirfenidone or nintedanib treatments.

Estriol therapy shifts Th1 to Th2 cytokines, reducing inflammation and disease progression without steroid side effects.

Topical Corynebacteria administration establishes a protective microbial barrier on cutaneous wounds to limit pathogenic bacterial colonization.

A siRNA-based pharmaceutical composition targets angiopoietin-like protein 2 expression in cardiomyocytes to enhance cardiac function.

Amide derivatives bind to the neuropeptide Y Y5 receptor, offering improved efficacy and reduced side effects for mood disorder treatment.

A single-stranded oligonucleotide couples an antisense sequence to a complementary RNA strand via a non-nucleotide linker.

Combining MEK and KRas G12C inhibitors overcomes insufficient single-agent efficacy.

Electron beam sterilization avoids gamma radiation degradation in hypercompressed lactide and glycolide polymers, preserving API stability.

A compound inhibits inflammatory responses in human aortic endothelial cells.

Formulation avoids sedimentation by removing bulk sweeteners, using xanthan gum and glycerol for stable suspension.

Replacing phosphoester bonds with phosphonate bonds prevents hydrolysis by phosphodiesterases, maintaining stability in biological environments.

Quinoxaline derivatives target FGFR kinase sites with enhanced specificity.

Modified peptides block toxic endogenous effects and cross the blood-brain barrier, resolving efficacy and side effect trade-offs.

Quinazolinone derivatives with tailored R-groups selectively inhibit cancer cell pathways while sparing normal cells.

Albumin-stabilized paclitaxel nanoparticles improve survival and response rates while minimizing side effects in metastatic pancreatic cancer.

Targeting CLOCK protein palmitoylation restores circadian rhythms, increasing myogenesis and reducing adipogenesis to treat metabolic disorders.

A transdermal patch uses non-functional acrylic adhesive with water-soluble organic amine and fatty acid ester to deliver serotonin receptor antagonists.

Low-dose digoxin resolves cardiac toxicity trade-offs by treating NASH through HIF-1α inhibition without significant side effects.

A composite injection of platelet-rich plasma, extracellular matrix, and triamcinolone acetonide enhances graft survival.

A PAC1 receptor antagonistic drug treats inflammatory and neuropathic pain using a nitrogen-containing heterocyclic lactam structure.

A CXCR4 inhibitor combined with multi-tyrosine kinase therapy blocks escape pathways.

Lipid nanoparticle formulations solubilize fenretinide to bypass oral absorption saturation and achieve cytotoxic plasma concentrations.

Segmented aminoheterocyclic structures overcome medication resistance by providing selective Rho kinase inhibition for resistant conditions.